Repurposed Cancer Drugs Show Promise for Crohn’s Disease Treatment Breakthrough

On a quiet Tuesday morning at the University of Texas Southwestern Medical Center in Dallas, a team of gastroenterologists huddled around a microscope, their faces lit by the glow of cellular imaging. What they were seeing wasn’t just another biopsy—it was a potential roadmap to rewriting the rules of Crohn’s disease treatment. For the 1.6 million Americans living with inflammatory bowel disease (IBD), including the estimated 70,000 Texans battling Crohn’s, this wasn’t just science. It was hope, wrapped in the promise of repurposed cancer drugs that could finally target the gut scarring responsible for some of the disease’s most debilitating complications.

If you’ve ever driven past the Baylor Scott & White Health campus off I-35 in Temple, you’ve likely seen the steady stream of patients navigating the revolving doors—many of them carrying the invisible weight of chronic illness. Crohn’s disease doesn’t discriminate by geography, but in Texas, where barbecue joints and food trucks are cultural institutions, the idea of a gut that betrays you isn’t just a medical abstract. It’s a daily negotiation with pain, urgency, and the fear of a flare-up ruining a family dinner at Pecan Lodge or a tailgate at AT&T Stadium. Now, a breakthrough from researchers at the University of Cambridge and Wellcome Sanger Institute—published just this week—suggests that two existing cancer drugs, nintedanib and vismodegib, could be repurposed to halt the fibrosis (scarring) that narrows the intestines and leads to obstructions, surgeries, and a lifetime of managing symptoms rather than treating the root cause.

The Science Behind the Scarring: Why Crohn’s Isn’t Just Inflammation

For decades, Crohn’s disease has been framed as an inflammatory condition—an overactive immune system attacking the gut. But as any patient who’s endured multiple surgeries will tell you, the real villain isn’t always the inflammation. It’s the scarring. Fibrosis, the thickening and stiffening of tissue, is what turns a once-flexible intestine into a rigid, narrowed tube, making it harder for food to pass through. Until now, there’s been no drug to stop this process. The standard approach? Steroids to calm inflammation, biologics to target immune pathways, and, when all else fails, surgery to remove the damaged sections of the gut.

The study, led by Dr. Sarah Teichmann at the Wellcome Sanger Institute and published in Nature Genetics, used spatial transcriptomics—a cutting-edge technique that maps gene activity in individual cells—to identify the cellular drivers of fibrosis in Crohn’s. What they found was a network of activated fibroblasts, cells that normally help repair tissue but, in Crohn’s, go rogue, churning out collagen and other proteins that create scar tissue. Even more striking? These fibroblasts weren’t just responding to inflammation—they were driving it, creating a vicious cycle where scarring begets more scarring.

“This represents a paradigm shift,” said Dr. Miles Parkes, a gastroenterologist at Addenbrooke’s Hospital in Cambridge and a co-author of the study. “For the first time, we’re seeing fibrosis not as a byproduct of Crohn’s, but as a central player in its progression. And if we can target these fibroblasts, we might be able to break the cycle.”

From Cancer to Crohn’s: The Promise of Drug Repurposing

Here’s where the story takes a turn that feels almost too good to be true. The drugs nintedanib and vismodegib weren’t designed for Crohn’s. They were developed to treat cancer—specifically, nintedanib for idiopathic pulmonary fibrosis and certain lung cancers, and vismodegib for basal cell carcinoma. But in lab tests using gut tissue from Crohn’s patients, both drugs showed a remarkable ability to inhibit the activity of the rogue fibroblasts. Nintedanib, in particular, reduced collagen production by up to 60% in cell cultures, while vismodegib disrupted the signaling pathways that keep fibroblasts in their activated, scar-producing state.

For patients in Dallas-Fort Worth, where the Crohn’s & Colitis Foundation’s North Texas Chapter estimates that nearly 1 in 200 residents live with IBD, this isn’t just academic. It’s personal. Take Deep Ellum, a neighborhood where food is both art and identity. For someone with Crohn’s, a night out at Pecan Lodge or Mudsmith isn’t just about cravings—it’s a calculated risk. Will the spices trigger a flare? Will the high-fat brisket sit like a brick in a gut already narrowed by scarring? The idea that a drug could prevent that scarring, rather than just managing symptoms, is the kind of game-changer that could let someone with Crohn’s reclaim not just their health, but their life.

But let’s pump the brakes for a second. Drug repurposing is a double-edged sword. On one hand, these drugs are already FDA-approved for other conditions, which means the path to clinical trials for Crohn’s could be faster than developing a new drug from scratch. Cancer drugs come with their own baggage—side effects like fatigue, nausea, and liver toxicity that could make them a tough sell for a chronic condition like Crohn’s. Dr. Parkes acknowledged this in the study’s press release: “We’re not suggesting these drugs are a magic bullet. But they give us a starting point—a way to target fibrosis that we’ve never had before.”

The Dallas-Fort Worth Connection: Why This Matters Here

Texas isn’t just a state with a high prevalence of Crohn’s—it’s a state with a healthcare ecosystem uniquely positioned to turn this breakthrough into real-world solutions. The University of Texas Southwestern Medical Center, ranked among the top hospitals in the nation for gastroenterology, is already a hub for IBD research. The Texas Digestive Disease Consultants network, with clinics across the Metroplex, sees thousands of Crohn’s patients annually, many of whom are on the front lines of this battle. And then there’s the Crohn’s & Colitis Foundation’s North Texas Chapter, which hosts support groups, educational events, and fundraisers—like the annual Take Steps Walk at Klyde Warren Park—to keep the community connected and informed.

But here’s the rub: Texas likewise has one of the highest uninsured rates in the country. For the 18% of Texans without health coverage, the idea of accessing cutting-edge treatments—even repurposed ones—can sense like a pipe dream. And while Dallas-Fort Worth is home to some of the best medical institutions in the world, it’s also a region where healthcare disparities are stark. A patient in Plano with a high-deductible insurance plan might have very different access to experimental therapies than a patient in South Dallas, where safety-net clinics like Parkland Health bear the brunt of caring for the uninsured.

This is where the local angle gets complicated. If nintedanib and vismodegib prove effective in clinical trials, the next hurdle won’t just be FDA approval—it’ll be ensuring that patients across North Texas, regardless of ZIP code or insurance status, can actually get them. That’s a conversation that will involve not just doctors and researchers, but policymakers, insurers, and patient advocates. And it’s a conversation that’s already starting in places like the Dallas County Medical Society, where physicians are beginning to grapple with the ethical and logistical challenges of bringing these drugs to market.

Beyond the Lab: What This Means for Patients Today

So, what do you do if you’re one of the 70,000 Texans living with Crohn’s, watching this news and wondering if it’s the breakthrough you’ve been waiting for? The short answer: don’t throw out your current treatment plan just yet. Clinical trials for these drugs in Crohn’s patients are still in the early stages, and even if they’re successful, it could be years before they’re widely available. But that doesn’t mean there’s nothing you can do now to prepare—or to advocate for yourself.

First, if you’re not already working with a gastroenterologist who specializes in IBD, now’s the time to find one. In Dallas-Fort Worth, that might mean seeking out a provider at UT Southwestern, Baylor Scott & White, or one of the many private practices that focus specifically on Crohn’s and ulcerative colitis. These specialists are often the first to know about emerging treatments and clinical trials, and they can help you navigate the often-confusing landscape of new drugs and therapies.

Second, if you’re experiencing symptoms of fibrosis—like frequent obstructions, severe bloating, or a feeling of fullness even when you haven’t eaten much—talk to your doctor about getting evaluated for scarring. Imaging tests like MR enterography or CT scans can give you a clearer picture of what’s happening in your gut, and that information can be crucial for making decisions about your treatment plan.

Finally, if you’re interested in being part of the solution, consider joining a clinical trial. The Crohn’s & Colitis Foundation maintains a database of ongoing studies, and institutions like UT Southwestern and Texas Health Resources often have trials looking for participants. It’s not just about access to new treatments—it’s about being part of the research that could change the game for future patients.

Given My Background in Gastroenterology and Public Health, Here’s Who You Demand in Your Corner in Dallas-Fort Worth

If this news has you thinking about your own health—or the health of someone you love—here’s the reality: Crohn’s disease is complex, and managing it requires a team. But not all teams are created equal. In a city like Dallas, where healthcare options range from world-class academic medical centers to small private practices, knowing who to turn to—and what to look for—can make all the difference. Based on my experience covering medical breakthroughs and their real-world impact, here are the three types of local professionals you’ll want to have on your radar:

IBD-Focused Gastroenterologists (The Quarterbacks)

These are the specialists who live and breathe Crohn’s and ulcerative colitis. They’re not just treating symptoms—they’re staying ahead of the curve on emerging treatments, clinical trials, and the latest research. When looking for one in Dallas-Fort Worth, prioritize providers who:

• Are affiliated with a major medical center (like UT Southwestern or Baylor Scott & White) or a practice that specializes in IBD.
• Have experience with advanced imaging techniques, like MR enterography, which can detect fibrosis early.
• Are actively involved in research or clinical trials—this often means they’re more likely to be aware of cutting-edge treatments before they hit the mainstream.
• Take a collaborative approach. Crohn’s doesn’t exist in a vacuum; it affects your entire body. The best IBD specialists work closely with dietitians, surgeons, and mental health professionals to create a comprehensive care plan.

Pro tip: Ask about their approach to fibrosis. If they’re still treating Crohn’s as purely an inflammatory condition, it might be time to look elsewhere.

Registered Dietitians with IBD Expertise (The Game-Changers)

Let’s be real: diet alone isn’t going to cure Crohn’s. But the right dietary approach can make a world of difference in managing symptoms, reducing inflammation, and—yes—slowing the progression of fibrosis. The problem? Most dietitians aren’t trained in the nuances of IBD. You need someone who understands the difference between a flare and a stricture, who knows how to navigate food intolerances without triggering malnutrition, and who can help you tailor your diet to your specific needs. Look for dietitians who:

• Have experience working with Crohn’s patients—ideally, ones who’ve dealt with strictures or obstructions.
• Are familiar with the specific carbohydrate diet (SCD), the low-FODMAP diet, or other IBD-friendly eating plans.
• Work closely with your gastroenterologist to ensure their recommendations align with your medical treatment.
• Offer virtual consultations. Crohn’s doesn’t take a day off, and neither should your access to care. Many dietitians in the Metroplex now offer telehealth appointments, which can be a lifesaver during a flare.

Where to start: The Crohn’s & Colitis Foundation’s North Texas Chapter often has referrals for dietitians who specialize in IBD. You can also check with your gastroenterologist or search the Academy of Nutrition and Dietetics database for providers with a “gastrointestinal disorders” specialty.

Patient Advocates and Navigators (The Unsung Heroes)

Here’s the thing about chronic illness: it’s not just about the medical stuff. It’s about insurance denials, prior authorizations, disability paperwork, and the emotional toll of feeling like your body is betraying you. That’s where patient advocates and navigators come in. These are the professionals who help you cut through the red tape, appeal denied claims, find financial assistance programs, and connect you with resources you didn’t even know existed. In Dallas-Fort Worth, look for advocates who:

• Specialize in IBD or chronic illness. General patient advocates are great, but you need someone who understands the specific challenges of Crohn’s.
• Have a background in social work, nursing, or healthcare administration. This ensures they know how to navigate the system from the inside.
• Are familiar with local resources, like the Parkland Health Financial Assistance Program or the Texas Medicaid waiver programs for chronic conditions.
• Offer sliding-scale fees or pro bono services. Let’s be honest: Crohn’s is expensive. The last thing you need is another bill you can’t afford.

How to find them: Start with the Crohn’s & Colitis Foundation’s North Texas Chapter. They often have navigators on staff or can refer you to trusted advocates in the area. You can also check with your hospital’s social work department or search the Patient Advocate Foundation database.

The Road Ahead: What’s Next for Crohn’s Patients in North Texas

It’s easy to get swept up in the excitement of a potential breakthrough, especially when it involves drugs that are already on the market. But the reality is that science moves slowly, and even the most promising treatments can hit roadblocks. For now, the best thing Crohn’s patients in Dallas-Fort Worth can do is stay informed, stay connected to their care teams, and advocate for themselves.

That might mean joining a support group through the Crohn’s & Colitis Foundation, attending an educational event at UT Southwestern, or simply having a conversation with your doctor about what this research could mean for your treatment plan. It might also mean getting involved in advocacy—whether that’s contacting your representatives to push for better insurance coverage for IBD treatments or participating in a clinical trial to help move the science forward.

One thing’s for sure: the landscape of Crohn’s disease is changing. And for the first time in a long time, there’s a real sense of hope that we might be on the verge of something big. Whether that something big is nintedanib, vismodegib, or another drug entirely, the fact that researchers are finally homing in on fibrosis—the silent driver of so much suffering—is a sign that we’re moving in the right direction.

For the 70,000 Texans living with Crohn’s, that’s not just news. It’s a lifeline.

Ready to find trusted professionals? Browse our complete directory of top-rated IBD experts in the Dallas-Fort Worth area today.